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Humanized bone-marrow xenograft models that can monitor the long-term impact of gene-therapy strategies will help facilitate
evaluation of clinical utility. The ability of the murine bone-marrow microenvironment in NOD/SCID versus NOD/SCID/γ
chainnull mice to support long-term engraftment of MGMTP140K-transduced human-hematopoietic cells following alkylator-
mediated in vivo selection was investigated. Mice were transplanted with MGMTP140K-transduced CD34+ cells and transduced
cells selected in vivo. At 4 months after transplantation,levels of human-cell engraftment, and MGMTP140K-transduced cells in the
bonemarrowofNOD/SCID versusNSGmicevaried slightlyinvehicle-anddrug-treated mice.Insecondary transplants,although
equal numbers of MGMTP140K-transduced human cells were transplanted, engraftment was signiﬁcantly higher in NOD/SCID/γ
chainnull mice compared to NOD/SCID mice at 2 months after transplantation. These data indicate that reconstitution of
NOD/SCID/γ chainnull mice with human-hematopoieticcells represents a more promising model in which to test for genotoxicity
and eﬃcacy of strategies that focus on manipulation of long-term repopulating cells of human origin.
1.Introduction
Developmentofhumanized hematopoieticxenograftmodels
that can monitor both short- and long-term reconstitution
of human hematopoietic stem and progenitor cells (HSCs)
will be a necessity as hematopoietic stem cell gene therapy
trials continue to move forward and show promise in the
clinic[1–7]. Clearly the use of small and large animal models
has been an intricate component in paving the way for these
successes [8–24]. Adverse events, however, directly related
to retroviral-mediated insertional mutagenesis in human
trials, have been reported in some patients enrolled in gene-
therapyclinicaltrialsforseverecombinedimmunodeﬁciency
(SCID)-X1 [25, 26] and chronic granulomatous disease [7,
27]. In addition, as preclinical studies in nonhuman pri-
mates, dogs, and mice have progressed over the past decade,
development of leukemias most likely linked or initiated by
vector-mediated insertional mutagenesis have been reported
[28–33].Therefore, moreinvestigations areneededtounder-
stand retroviral-mediated genome instability in addition to
the design ofnew vectorsystems topreventthisadverse event
in human gene-therapy trials. The evaluation of both short-
and long-term reconstituting human HSC will be critical in
addressing these issues and is the focus of the current study.
In the past,i nv i v oexperiments designed to study the
engraftment and multilineage diﬀerentiation of human HSC2 Bone Marrow Research
were challenging since residual immune reactivity in the
animals could result in loss of transplanted human HSC.
Additionally, transplant of human HSC into NOD/SCID
mice, for example, was typically a short-term 3-4 month
assay. With the introduction of new immunodeﬁcient strains
such as the NOD/SCID/γ chainnull mouse (NSG), long-
term analysis of engrafted human hematopoietic cells is
now a reality and represents a signiﬁcant improvement
over the commonly used NOD/SCID mouse for studies
focused on in vivo analysis of human HSC function [34].
The NSG mice are deﬁcient in the Interleukin-2 receptor
(IL2R) common γ chain which is an essential component
of multiple cytokine receptors-IL-2, IL-4, IL-7, IL-9, IL-15,
and IL-21; this mutation results in a substantial decrease in
overall immune function in this mouse strain. In contrast to
the NOD/SCID mouse, this additional defect in NSG mice
causes a signiﬁcant block in natural killer-cell development
and makes them less susceptible to lymphoma development
which allows for an increased life span (NSG = 16 months
versus NOD/SCID = 8–10 months). With the increased life
span, these miceshould beamendable tolong-termfollowup
of human HSC function.
Studies using small and large animal models continue
to investigate the consequences of genotoxic stress on
retrovirally transduced HSC. A powerful tool for in-vivo
selection of HSC, a mutant form of O6-methylguanine
DNA methyltransferase DNA repair protein (MGMT)-
MGMTP140K-has shown promise in nonhuman primates,
mice, and humanized xenograft models. Overexpression
of MGMTP140K in HSC, which is resistant to the MGMT
inhibitor, O6-benzylguanine (6BG) allows for selection and
protection of the MGMTP140K-transduced HSC following
administration of 6BG in combination with alkylators such
as BCNU, CCNU, or temozolomide [35]. If MGMTP140K
expression is adequate in the HSC, it should also protect
the HSC from high-dose alkylator therapy required in some
cancer treatments and thereby prevent therapy-induced
myelotoxicity.GenerationofHSCthateﬃcientlyrepairDNA
damage due to chemotherapy may protect patients from life-
threatening cytopenias commonly observed following dose-
intensiﬁed therapy. A case in point, in recent phase II clin-
ical trials, patients with nitrosourea-resistant gliomas were
simultaneously treated with 6BG to deplete MGMT in the
cancer cells, followed by treatment with the DNA-damaging
agents, BCNU or temozolomide [36, 37]. Although lack of
tumorprogressionwastransientlyobservedinsomepatients,
eﬀective dose-escalation therapy could not be achieved
due to severe hematopoietic toxicity. These studies provide
clinical proof that strategies protecting HSC during dose-
intensiﬁed therapy are indeed clearly needed in relapsed
patients requiring high-dose alkylator therapy. In addition,
expression of MGMTP140K in HSC can be used as a means
to preferentially select and amplify small populations of
MGMTP140K-transduced cells in the bone marrow. However,
long-term impact of this treatment in humanized mouse
models which include secondary transplantation has not
been investigated. To what extent administration of even
low doses of chemotherapeutic drugs such as BCNU or
TMZ could have on long-term human hematopoiesis is not
well understood and secondary malignancies are always a
concern.
Repetitive low-dose treatment for in vivo selection of
MGMTP140K-transduced cells has been successful in mice
and large animal models [8, 16]. Numerous transplant
studies have convincingly proven that long-term repopu-
lating murine stem cells could be selected in vivo with
6BG/BCNU, 6BG/TMZ, or 6BG/CCNU [9, 11, 14, 17, 18,
20, 21, 38–40]. In regards to modeling of this approach
with human HSC, we and others previously demonstrated
that MGMTP140K-transduced SCID-repopulating cells and
their progeny could be selected in vivo in NOD/SCID
mice [19, 24]. Human HSC derived from umbilical cord
blood (UCB) or granulocyte colony-stimulating factor (G-
CSF)-mobilized peripheral blood (MPB) that expressed
MGMTP140K could be selected in vivo by nonmyeloablative
doses of 6BG and BCNU. Zielske et al. also reported
similar results using MGMTP140K-transduced UCB in the
NOD/SCID xenograft model [24]. Additionally, our labora-
tory went on to investigate the extent to which MGMTP140K-
transduced human SCID-repopulating cells and progeny
could be protected in vivo by MGMTP140K expression during
delivery of high-dose alkylator therapy that kills cancer cells.
In this study, we compared the outcome of administering a
low-dose 6BG/BCNUregimenversusa high-dose regimenin
NOD/SCIDmice transplanted withMGMTP140K-transduced
mobilized peripheral blood CD34+ cells. We found that, at
least in the NOD/SCIDxenograft model, when human MPB
were transduced with an oncoretroviral vector that expresses
MGMTP140K, only low numbers of human MPB cells were
protected following delivery of the myeloablative regimen
and that these cells were limited to mature lymphoid and
myeloid cells [10]. In all these studies, NOD/SCIDmice were
used and analysis of long-term reconstitution in secondary
recipient mice was not determined.
The objective of our current study was to determine
to what degree long-term human SCID-repopulating cells
could be selected in vivo by alkylator therapy and to
compare the levels of selection in primary and secondary
NOD/SCID and NSG mice. Our data demonstrate that
human hematopoietic cells of multiple lineages were capable
of expressing MGMTP140K for at least 4 months in primary
recipients and in vivo-selected populations while not as
robust as nonselected populations, were able to home and
engraft in the bone marrow of secondary recipient NSG
months for at least an additional 2 months. In contrast to
the NOD/SCID xenograft model, the NSG bone-marrow
microenvironment appears to allow for optimal reconsti-
tution and feasibility of long-term followup of human
hematopoiesis.
2.Materialsand Methods
2.1. Animals. Breeding colonies of NOD.Cg-Prkdcscid
(NOD/SCID) and NOD.Cg-Prkdcscid IL2rgtm1Wjl/Sz (NSG)
mice [34] was established at the Laboratory Animal Research
Center and maintained in the In Vivo Therapeutics Core
at the Indiana University Simon Cancer Center (IUSCC)Bone Marrow Research 3
(Indianapolis, IN). All protocols and were approved by the
Institutional Animal Care and Use Committee at the Indiana
University School of Medicine.
2.2. Isolation of Umbilical Cord Blood (UCB) CD34+ Cells.
All protocols were approved by Indiana University School
of Medicine’s Institutional Review Board (IRB) and St.
Vincent Hospital’s IRB (Indianapolis, IN). Samples of UCB
were collected from normal, full-term infants delivered by
cesarean section and the CD34+ cells isolated using the
C D 3 4M i c r o B e a dk i ta n dV a r i o M A C SS e p a r a t o r( M i l t e n y i
Biotech Inc., Auburn, CA) according to the manufacturer’s
instructions.
2.3. Retrovirus Backbones for Expression of MGMTP140K in
CD34+ Cells. The oncoretroviral vector, SF1-MGMTP140K-
IRES-EGFP (SF1-P140K) was utilized to coexpress
MGMTP140K and EGFP in human CD34+ cells and has
been described previously [10]. Retroviral vectors were
pseudotyped with the gibbon ape leukemia virus envelope
(GALV) using the PG13 packaging cell line (American Type
Culture Collection, Manassas, Va.) [41]. Titers were initially
determined on human erythroleukemia (HEL) cells by
limiting-dilution analysis.
2.4. Transduction of UCB CD34+ Cells. The transductions
were done as previously described by our laboratory [10,
19, 42]. The starting cell number prior to prestimulation
and transduction was 4 × 105 per mouse transplanted.
Isolated CD34+ cells were prestimulated at a cell density of
5 × 105 cells per ml in Ex Vivo-10 serum-free medium-
containing 1% human serum albumin. The medium was
supplemented with Granulocyte-Colony Stimulating Factor
(G-CSF), stem cell factor (SCF), and thrombopoietin (TPO)
(PeproTech, Rocky Hill, NJ). Each cytokine was used at
100ng/mlforprestimulation.Nontissueculture10-cmplates
(Falcon, Franklin Lakes, NJ), were coated with 2μg/cm2
Retronectin—(Takara Shuzo, Otsu, Japan) overnight at
4◦C. Cells were plated at a concentration of 2 × 105
cells per cm2 for transduction. Cells were infected with a
1:1 ratio of retrovirus supernatant:complete media with
cytokines for 4 hours on 2 consecutive days, with a change
to complete medium-containing cytokines for overnight
incubation. After the second round of infection, cells were
allowed to remain overnight on Retronectin-coated plates
withfresh mediumandcytokinesandthentransplanted. The
transductioneﬃciencywasdeterminedbyﬂowcytometryon
the day of the transplant. For secondary transplants, bone-
marrow cells were resuspended at 1 × 106 per ml in Ex
Vivo-10 serum-free medium-containing 1% human serum
albumin,100ng/mlSCF,and 100ng/mlIL-6 (PeproTech)for
36–48 hours prior to transplantation.
2.5. Transplantation of NOD/SCID and NSG Mice with
Human CD34+ Cells. Immunodeﬁcient mice were placed
on food pellets containing 0.0625% doxycycline for 5–
7 days prior to irradiation. Mice were then conditioned
with 300-cGy total-body irradiation using a GammaCell
40 (Nordion International Inc., Ontario Canada) equipped
with two opposing Cesium-137 sources. UCB CD34+ cells
were resuspended in IMDM containing 0.2% endotoxin-free
bovine serum albumin and injected into the lateral tail vein
of each animal.
2.6.ChemotherapyAdministration. O6-benzylguanine (6BG)
(Sigma-Aldrich, St Louis, MO) was dissolved in 40%
polyethylene glycol-400 (v/v) and 60% saline (v/v). BCNU
(Sigma) was dissolved in 10% ethanol (v/v) and 90% normal
saline solution (v/v). BCNU was placed on ice and used
immediately after reconstitution. One cycle of treatment
consisted of 20mg/kg 6BG followed by 5mg/kg BCNU one-
hour later. Two cycles of treatment were delivered one week
apart.
2.7. Analysis of Human Cell Engraftment. Mice were sac-
riﬁced at 8 weeks after 6BG/BCNU injection and single-
cell suspensions of the bone marrow (BM) prepared as
previously described [10, 19, 42]. Human cell engraftment
measured by human CD45 staining and the proportion
of engraftment in various lineages was determined by
immunostaining and ﬂow cytometric analysis. Aliquotsof 1-
2 × 105 cells/tubewere stained with various antibodies for25
minutes at 4◦C in complete medium and washed 1 time in
PBS containing 1% FBS. All antibodies were titered and used
at saturating concentrations. The lack of crossreactivity of
human-speciﬁc antibodies with murine cells was conﬁrmed
in every experiment by staining BM from a nontransplanted
mouse with each antibody combination. Cells were stained
with Allophycocyanin (APC)-conjugated anti-human-CD45
(anti-HLe-1; BectonDickinsonImmunocytometry, SanJose,
CA) alone or in combination with phycoerthyrin (PE)-
conjugated anti-human CD33 (anti-Leu-M9; Becton Dick-
inson). Identical aliquots were stained with APC-conjugated
anti-human CD34 (clone 581; PharMingen, San Diego, CA)
incombinationwithanti-human CD19-PE(PharMingen) or
anti-human CD38-PE (anti-Leu-17; BectonDickinson). The
forward andright-angle lightscatterparameters were usedto
set the gates for analysis. In experiments where engraftment
of human cells was >5%, ∼20,000–40,000 events were
collected and analyzed. In experiments in which human
engraftment was <5% ∼200,000 events were collected and
analyzed. All samples were acquired and analyzed on a
Becton-Dickinson FACSCalibur using CellQuest software
(Becton-Dickinson).
2.8. Statistical Analysis. The Mann-Whitney U-test was
utilized to determine statistical signiﬁcance. Diﬀerences
between mouse cohorts were considered signiﬁcant at P<
.05 using two-sided tests.
3.Results
3.1. Comparison of Human Hematopoietic Cell Engraftment
in NSG versus NOD/SCID Mice. In order to gain a better
understanding of the engraftment capabilities of NSG and
NOD/SCID mice, we ﬁrst evaluated the engraftment of4 Bone Marrow Research
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Figure 1: Comparison of human hematopoietic cell engraftment
in NSG versus NOD/SCID mice. Nonmanipulated umbilical cord
blood CD34+ cells (1 × 104–5 × 104 per mouse) were transplanted
into sublethally irradiated (300cGy) NSG or NOD/SCID mice and
human cell engraftment in the bone marrow (% human CD45+
cells) analyzed 8 weeks later by ﬂow cytometry. Multi-lineage
engraftment was similar in both strains (data not shown). n = 4
mice per cohort; ∗NS2 versus NOD/SCID, P<. 001.
nontransduced UCB CD34+ cells transplanted into NSG
versus NOD/SCID mice. Cohorts of sublethally irradiated
NSGandNOD/SCIDmiceweretransplanted withincreasing
numbers of nonmanipulated, freshly isolated UCB CD34+
cells (1.0–5.0 × 104 per mouse). At 2 months after trans-
plantation, the bone marrow was harvested and analyzed
for the engraftment of human cells (Figure 1). Human
hematopoietic cells engrafted in all NSG and NOD/SCID
mice but at higher levels in NSG versus NOD/SCID mice.
Engraftment levelsin the NSG mice was ∼3-fold higher than
levels observed in the NOD/SCIDmice.
3.2. 6BG/BCNU-Mediated In Vivo Selection of MGMTP140K-
Transduced UCB CD34+ Cells in Primary Recipient NOD/
SCID and NSG Mice. Human umbilical cord blood CD34+
cells were next transduced with a GALV-pseudotyped
oncoretroviral vector, SF1-MGMTP140K-IRES-EGFP pre-
viously shown by our group to express high levels
of MGMTP140K in NOD/SCID mice transplanted with
MGMTP140K-transduced human cells [10]. The transduction
eﬃciency was determined by EGFP expression in bulk
CD34+ cells and clonogenic cells and was 65% and 60%
EGFP+, respectively, (data not shown). Equal numbers of
transduced cellswere transplanted into sublethally irradiated
(300cGy) NSG or NOD/SCID mice (Figure 2). A relatively
large number of UCB CD34+ cells were transplanted per
mouse (4 × 105 total CD34+ cells) so suﬃcient numbers
of human cells could be obtained for the secondary trans-
plants following the in vivo selection and recovery period.
One month after transplantation, mice received 2 cycles
administered one week apart consisting of 20mg/kg 6BG
followed one hour later with 5mg/kg BCNU. At 4 months
after transplantation, the bone marrow was harvested and
2d a y s
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NSG 6BG + BCNU
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2 cycles of
transduction =
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Figure 2: Overview of primary and secondary reconstitution
experiments in NSG versus NOD/SCID mice. Human umbil-
ical cord blood CD34+ cells were transduced with a GALV-
pseudotyped oncoretroviral vector, SF1-MGMTP140K-IRES-EGFP
(MO1 = 5) and transduced cells transplanted into sublethally
irradiated (300cGy) NSG or NOD/SCID mice. One month after
transplantation,cells were selected in vivo with 2cycles of20mg/kg
6BG followed one hour later with 5mg/kg BCNU. At 4 months
after transplantation, the bone marrow was harvested and analyzed
for the presence of human cells by ﬂow cytometry. Bone marrow
cultures were prestimulated in IL-6 and SCF for 48 hours and then
equal numbers ofhumanbone-marrow cells were transplanted into
secondary recipient NSG and NOD/SCID mice. At 2 months after
transplant, the secondary mice were analyzed for the presence of
human cells via ﬂow cytometry.
analyzed for the presence of human cells by ﬂow cytometry.
Both mouse strains contained high levels of human-cell
engraftment in the bone marrow (Figure 3(a))a n din
vivo selection of transduced cells with 6BG/BCNU was
achieved in both mouse strains (Figure 3(b)). However, the
overall human engraftment (human CD45+ cells) in vehicle-
treated NOD/SCID mice was slightly decreased compared
to engraftment in vehicle-treated NSG mice (Figure 3(a),
vehicle-treated NOD/SCID mice-69%± 8% versus vehicle-
treated NSG mice-81%± 4 ) .I na d d i t i o n ,t h ev a r i a b i l i t yo f
human-cell engraftmentwithinthedrug-treatedNOD/SCID
cohort was more pronounced than that seen in the drug-
treated NSG cohort (Figure 3(a),d r u g - t r e a t e dN O D / S C I D
mice-63%± 32% human CD45+ cells versus drug-treated
NSG mice-76%± 10% human CD45+ cells). In the drug-
treated NOD/SCID mice for example, 2/8 exhibited a sig-
niﬁcant decreaseinhuman chimerismfollowing 6BG/BCNUBone Marrow Research 5
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Figure 3: Comparison of in vivo selected MGMTP140K-transduced
humancells inNSGandNOD/SCIDmice.Thestartingcell number
was 4 × 105 cells per transplanted mouse. MGMTP140K-transduced
CD34+ cells were transplanted into NS2 and NOD/SCID mice and
selected in vivo as outlined in Figure 2. The BM was harvested and
analyzed for the level of total human cell engraftment (%huCD45+
cells) and the level of transduced human cells (%huCD45+EGFP+)
by ﬂow cytometry. The BM cellularity was similar between the
NSG and NOD/SCID mice and the diﬀerences in total human
engraftment in NSG versus NOD/SCID mice were not signiﬁcant
(P>. 05).The datapresented here are from1transplantexperiment
(n = 3-4 mice in vehicle-treated cohorts and n = 8m i c ei n
6BG/BCNU-treated cohorts). Similar results were obtained in a
second independent transplant experiment.
whereas human-cell engraftment remained more consistent
within the NSG drug-treated cohort (Figure 3(a)).
While signiﬁcant in vivo selection of human
MGMTP140K-transduced cells was clearly evident at
4 months after transplant regardless of the mouse strain,
these data indicate that the microenvironment of the NSG
mouse which is devoid of murine NK-cell activity may be
more amendable for the in vivo selection and ampliﬁcation
of transduced human cells. A detailed ﬂow cytometric
analysis was also performed to see if any speciﬁc cell lineage
was preferentially aﬀected by the in vivo s e l e c t i o ni nt h e
mouse strains. While the variability in the percentages
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Figure 4: Analysis of human CD34+ c e l l si nt h eb o n em a r r o wo f
primary recipient vehicle- and 6BG/BCNU-treated mice. (a) The
percentage of total human CD34+ cells and (b) CD34+ human
cells that are EGFP+ (huCD34+EGFP+) was determined by ﬂow
cytometry at 8 weeks after drug treatment. ∗P<. 001,vehicleversus
6BG/BCNU treated.
of human CD34+ c e l l sw a sl a r g e ri nt h ed r u g - t r e a t e d
NOD/SCID mice than the NSG mice, it did not reach
statistical signiﬁcance (Figure 4(a)). Consistent with the
overall in vivo selection data presented in Figure 3,t h e r e
was a signiﬁcant increase in the in vivo-selected CD34+
cells in vehicle- versus drug-treated regardless of the mouse
strain used indicating a selection and some expansion
of the human EGFP+,C D 3 4 + cells in the bone marrow
(Figure 4(b)). The outcome of 6BG/BCNU treatment on
multilineage diﬀerentiation typically found in the bone
marrow of NOD/SCID and NSG mice reconstituted with
human cells was next evaluated (Figure 5). In vehicle-treated
primary recipient NSG and NOD/SCID mice, similar
percentages of total and transduced CD34+ progenitor,
human B-lymphoid, and myeloid cells were present in the
human bone-marrow grafts. Human bone-marrow grafts
in vehicle-treated NSG and NOD/SCID mice consisted of
10–15% CD34+ progenitor, 65–80% B-lymphoid, and 10–
20% myeloid cells, and 20–30% of these lineages expressed
EGFP (data not shown). In 6BG/BCNU-treated NSG and
NOD/SCID mice, a signiﬁcant selection of human EGFP+
cells was evident in CD34+ progenitor, CD19+ B-lymphoid6 Bone Marrow Research
and human CD33+ myeloid cells with at least 88% of
these cell lineages expressing EGFP+ at 8 weeks after drug
treatment (Figure 5).
3.3. Secondary Reconstitution of NOD/SCID and NSG Mice
withMGMTP140K-Transduced UCBCD34+ Cells Derived from
NOD/SCID and NSG Mice. Peled et al. originally demon-
strated that secondary reconstitution of immunodeﬁcient
mice is improved by exposure to IL-6 and SCF prior to
retransplantation [43]. The primary mechanism for the
enhancement in repopulating ability is increased expression
of the CXCR-4 receptor previously shown to play a key
role in the homing of transplanted cells. In agreement with
theseobservations,wefoundthatIL-6/SCFprestimulationof
human bone-marrow culturesderivedfrom the transplanted
NOD/SCID or NSG mice led to an increase or at least
maintenance of CXCR-4 expression on the surface of the
majority of the human cells (data not shown). Following
the 48-hour prestimulation period, 10 × 106 human CD45+
cells (vehicle or drug-treated) which contained similar
percentagesofCD34+ cellsweretransplanted intosublethally
irradiated NOD/SCID or NSG mice as outlined in Figure 2.
At 2 months after transplantation, the bone marrow of the
secondary recipient mice was analyzed for the percentage
of total human CD45+ cells (Figure 6(a))a n dE G F P +
human CD45+ cells (Figure 6(b)). Even though equivalent
numbers of transduced human cells from primary recipient
NOD/SCIDand NSGmice were transplanted into secondary
recipient mice, striking and statistically signiﬁcant diﬀer-
ences in the level of engraftment between the NOD/SCID
and the NSG mice was observed (Figure 6(a)). Low levels
of engraftment were observed in secondary NOD/SCID
mice receiving human cells from vehicle-treated primary
NOD/SCID mice and ranged from 2%–4% human CD45+
cells with 25–45% of these human hematopoietic cells
remaining EGFP+. In addition, in NOD/SCID secondary
recipient mice transplanted with bone marrow from primary
recipient NOD/SCID mice previously drug treated, only 1
of 4 mice showed detectable levels of human cells (1.5%
human CD45+ cells). In comparison to the NOD/SCID
transplants, diﬀerent levels of human-cell engraftment were
found in the secondary transplant experiments using the
NSG mice. Human-cell engraftment was detected in all
secondary recipient NSG mice (Figure 6), although engraft-
ment levels were diﬀerent from that previously observed
in the primary transplanted NSG mice. Engraftment of
NSG mice receiving humanized bone marrow from vehicle-
treated mice was 55%–70% human CD45+ with 15–30% of
the cells transduced. Engraftment of secondary NSG mice
receiving humanized bone marrow from drug-treated mice
ranged from 4%–18% human CD45+ with EGFP+ cells
ranging from 15%–95%. While a signiﬁcant increase in the
percentage of EGFP+CD34+ cells was observed in the drug-
treated versus the vehicle-treated secondary recipient mice,
signiﬁcant diﬀerences were noted in the overall engraftment
levels of the CD34+ cells in the secondary recipient NSG
mice (Figure 7). A signiﬁcant decrease in the percentage
of CD34+ cells in the grafts derived from the drug-treated
mice compared to grafts derived from vehicle-treated mice
was evident and is consistent with decreased long-term
SCID-repopulating ability in the secondary recipient NSG
mice that received bone marrow from drug-treated pri-
mary NSG recipients. The impact of 6BG/BCNU treatment
on multilineage diﬀerentiation of human cells was next
evaluated (Figure 8) and a signiﬁcant selection of EGFP+
human cells was evident in multiple cell lineages in the
NSG mice. Increased percentages of EGFP+ cells were found
in populations of human hematopoietic CD34+ progenitor,
CD19+ B-lymphoid, and CD33+ myeloid cells derived from
the bone marrow of drug-treated NSG mice indicating
that secondary reconstituting SCID-repopulating cells were
capable of multilineage diﬀerentiation.
4.Discussionand Conclusions
Maintenance of genome stability in hematopoietic stem
and progenitor cells (HSC) following ex vivo manipulation
and transplantation will be essential for normal blood-cell
development. The objective of this study was to develop a
humanized bone-marrow xenograft model to follow long-
term reconstitution of genetically modiﬁed human HSC. We
determined if populations of in vivo-selected MGMTP140K-
transduced human HSC residing in the bone marrow
still contained suﬃcient SCID-repopulating cell activity to
reconstitutesecondary recipient animals. In this initial study,
our focus was to deﬁne the basic parameters of the model
so that adequateengraftment of HSCin secondary recipients
couldbeachieved.The MGMTP140K-transducedhumanHSC
underwent in vivo selection in the primary recipient mice
one-month after transplant and then the mice were allowed
to recover out to 4-months after transplant. We found that
while both the NOD/SCID and NSG models adequately
supported human HSC reconstitution and in vivo-selection
in the primary recipient mice, NSGmice were far superior to
the NOD/SCID model for secondary reconstitution. It will
now be possible to extend the post-transplant time frame,
and studies are currently in progress in which genetically
modiﬁed human HSC are being followed for at least a year
after transplantation.
With basic parameters of the model deﬁned, we are
continuing to developthis valuable xenograft model. Studies
are now in progress to test lenti- and foamy-viral vector
systems to determine if increased numbers of long-term
SCID-repopulating cells can be transduced. In addition,
the consistency of long-term transgene expression and
also analysis of retroviral-insertion sites in primary and
secondary transplanted animals in the absence and presence
of in vivo selection will be evaluated in these long-term
studies.
Since Natural-Killer cell precursor cells require expres-
sion of the common γ chain protein for development into
mature NK cells in vivo, lack of this protein will preclude
their development. The rejection of human hematopoietic
cells by murine NK cells in NOD/SCID mice is most
likely the primary reason for decreased engraftment of
the human CD34+ cells in the NOD/SCID mice but notBone Marrow Research 7
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Figure 5: Representative example of humanmultilineageengraftment in 6BG/BCNU-treated primary recipient mice. The bonemarrowwas
harvested at 8-weeks after drug treatment, and the level of total and transduced human progenitors (CD34+), B-lymphoid (CD19+), and
myeloid (CD33+) cells were determined via ﬂow cytometry. The level of transduced cells was similar between NOD/SCID and NSG mice.
The percentage in the upper right-hand quadrant represents the percentage of the human progenitor, B-lymphoid, or myeloid cells that are
EGFP+.
in the NSG mice. Others have shown previously that the
injection of anti-CD122 inhibits NK activity in NOD/SCID
mice and improves engraftment in the bone marrow [34,
44–48]. In order to begin to understand the mechanistic
diﬀerences seen in the engraftment levels of the two mouse
strains, we initially looked at the “engraftability” of non-
manipulated CD34+ cells in primary recipient NSG versus
NOD/SCID mice. Diﬀerences in the engraftment of the
SCID-repopulating cells in primary NSG versus NOD/SCID
recipients mice were apparent when low numbers of human
CD34+ cells were transplanted. Similar engraftgment results
in primary recipient NSGversus NOD/SCIDmice have been
recently reported by McDermott et al. [44]. It is important
to note that our data also demonstrated that when larger
numbers of transduced CD34+ cells were initially trans-
plantedintoprimaryrecipientsNOD/SCIDorNOD/SCID/γ
chainnull mice, diﬀerences in overall human engraftment
were evident but were not statistically signiﬁcant. However,
once the chimeric bone-marrow cells were transplanted
into secondary recipient animals, engraftment diﬀerences in
SCID-repopulating activity between NSG and NOD/SCID
were statistically signiﬁcant.
Bone-marrow cellularity was similar in the NSG and
NOD/SCID mouse cohorts indicating that the absolute
numbers of EGFP+ cells in the bone marrow in the vehicle-
and treated-mice in the primary NOD/SCID and NSG mice
were also similar. Flow cytometric analyses indicated that the
mean ﬂuorescence intensities for EGFP were also similar in
the EGFP+ populations found in both strains of mice (data
notshown).Wehavepreviouslyshown thatEGFPexpression
does correlate with MGMTP140K expression [10]. Therefore,
potential diﬀerences in transgene expression most likely do
not account for theengraftment diﬀerencesseenbetweenthe
NOD/SCIDand NSG mice.
While the major cellular diﬀerence noted in the original
paper by Shultz et al. was the lack of murine NK-cell devel-
opment [34], we cannot rule out that the function of other
cell types in the bone-marrow microenvironment could be
modulated by lack of the common γ chain expression and
thatthiscouldaﬀectthehoming, survival, expansion, and/or
diﬀerentiationofthehumanhematopoieticcells.Diﬀerential
engraftment diﬀerences observed in our study are consistent
with the hypothesis that the lack of mature murine NK
cells in the NSG mice allows for more optimal engraftment,8 Bone Marrow Research
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Figure 6: Analysis of human cell engraftment in secondary recipi-
ent NOD/SCID and NSG mice. (a) The percentage of total human
cells(%huCD45+)inthebonemarrowand(b)thepercentage ofthe
huCD45+ cells that are EGFP+ (%huCD45+EGFP+)w e r ea n a l y z e d
at 8 weeks after transplant into secondary recipient NOD/SCID
and NSG mice as outlined in Figure 2. ∗P<. 001, NSG versus
NOD/SCID. The date presented are from 1 transplant experiment
(n = 3 secondary recipient mice transplanted with BM from
vehicle-treated cohorts and n = 4–8 secondary mice transplanted
with BM from 6BG/BCNU-treated cohorts. Similar results were
obtained in a second independent transplant experiment.
survival, and diﬀerentiation of hematopoietic cell subsets
since murine NK cells are not present to destroy the human
grafts in the NSG mice.
Our data indicate that while we were able to detect
human HSC engraftment in secondary NSG mice trans-
planted with bone marrow from drug-treated primary mice
(4%–18% human CD45+), it did not approach the levels
of reconstitution seen in secondary NSG mice transplanted
with bone marrow from vehicle-treated mice (55%–70%
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Figure 7: Analysis of human CD34+ cells in secondary recipient
NSG mice transplanted with BM from vehicle- or 6BG/BCNU-
treated mice. (a) The percentage of total human CD34 cells
(%huCD34+) (b) the percentage of the human CD34+ cells that
are EGFP+ (%huCD34+EGFP+) in the bone marrow were analyzed
at 8 weeks after transplant into secondary recipient NSG mice by
ﬂow cytometry. The source of the bone-marrow cells that were
transplanted into the secondary recipient mice were derived from
vehicle- or6BG/BCNU-treated mice primary NSG mice. ∗P<. 001,
total CD34+ cells-vehicle versus 6BG/BCNU treated; ∗P<. 05,
transduced CD34+ cells-vehicle versus 6BG/BCNU treated.
human CD45+). Furthermore, the percentage of EGFP+ cells
in secondary NSG mice transplanted with bone marrow
from drug-treated primary mice cells varied from 15%
to 95%. Transgene expression was more uniform in the
drug-treated primary recipient mice (Figure 2(b)). It is not
clear at this time whether this decrease in the percent of
transduced cells has to do with silencing of the vector and/or
decreased SCID-repopulating cell activity in the transduced
population. No 6BG/BCNU treatment was administered in
the secondary recipient mice and future experiments will
also address the outcome of administering in vivo selective
pressure in the secondary recipient mice. Transplantation of
ex vivo manipulated HSC into NOD/SCID/γ chainnull mice
represents a feasible model in which to test and validate
novel strategies that focus on therapeutic manipulation of
long-term repopulating cells from human stem cell sources.
Umbilical-cord blood cells were utilized as the transplant
source in this study. It will be important to deﬁne the
long-term SCID-repopulating cell frequency in human bone
marrow and G-CSF-mobilized peripheral blood in the NSGBone Marrow Research 9
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Figure 8: Representative example of multilineage engraftment in secondary recipient NSG mice transplanted with BM from vehicle- or
6BG/BCNU-treated mice. The percentage of total human(CD45+) andtransduced human progenitors (CD34+), B-lymphoid(CD19+),and
myeloid (CD33+) cells in the bone marrowwere determined via ﬂow cytometry at 8 weeks after transplant in secondary recipient NSG mice.
Thepercentage intheupper right-handquadrantrepresents thepercentageofthehumancellsthatareEGFP+ intheprogenitor,B-lymphoid,
or myeloid cell subsets. The source of the bone-marrow cells that were transplanted into the secondary recipient mice were derived from
vehicle- or 6BG/BCNU-treated mice primary NSG mice.
mice since these sources will be used in human gene-
therapy trials, and typically have lower primary SCID-
repopulating cell frequencies than UCB [49], and can be
morerefractivetotransductionthanUCB-derivedHSC[42].
These data indicate that long-lived SCID-repopulating cells
can be transduced with oncoretroviral vectors and selected
in vivo and oﬀers a promising and unique model in which to
assess potential genotoxicity and ultimately optimize in vivo
selection strategies.
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